Quintiles to run Phase I diabetes trial for Kareus

By Zachary Brennan

- Last updated on GMT

Related tags: Metabolism, Pharmacology, Diabetes mellitus

Quintiles to run Phase I diabetes trial for Kareus
Kareus Therapeutics announced Wednesday that the US FDA has approved its Phase I clinical trial, which will be run by CRO Quintiles. 

The drug, known as KU-9k5039, is being developed for the treatment of insulin resistance​ and diabetes. The drug is a potent and selective activator of AMP-kinase, a key regulator of cellular and whole body energy homeostasis that coordinates metabolic pathways. Pharmacological activation of AMPK in animals promotes glucose uptake, fatty acid oxidation, mitochondrial biogenesis, and insulin sensitivity.

KU-5039 has shown therapeutic potential in animal models for the treatment of insulin resistance​ and diabetes. 

Quintiles will begin first-in-human trials to evaluate safety, tolerability and pharmacokinetics in a randomized, double-blind, placebo-controlled study. Quintiles did not respond to a request for comment.

The move follows Quintiles’ decision to shutter its Phase I unit in India​, acquire Novella​, and re-iterate its focus​ on large-scale deals. As of last summer, investment analysts seemed to offer a generally positive​ outlook on Quintiles stock.

Dr. Ish Khanna, head of preclinical at Kareus, said, "Our preclinical studies have established that KU-5039 is not only a potent insulin sensitizer in diabetic models but has superior side effects profile including no weight gain, no lactic acidosis and no hypoglycemia in comparison to currently available anti-diabetic drugs.​"

"This is a major milestone for Kareus, demonstrating the power of its innovation and ability to build a pipeline cost effectively,"​ said Dr. Uday Saxena, co-founder & head of R&D strategy of Kareus.

Related topics: Clinical Development, Phase I-II

Related news

Show more

Related products

show more

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

Empowering Clinical Trial Sponsors with Analytics

Empowering Clinical Trial Sponsors with Analytics

PerkinElmer | 14-Jul-2021 | Technical / White Paper

Is your Clinical Data Review creating problems or solving them? Take Control of Your Data. PerkinElmer Informatics Clinical Solutions, powered by Tibco...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

Related suppliers

Follow us

Products

View more

Webinars